ODM-207 in Patients With Advance Solid Tumours

Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic cancer for which no effective standard therapy exists or are refractory or resistant to conventional therapy * Life expectancy \>12 weeks * Patient may have either measurable or non-measurable disease, but must have disease that can be evaluated for improvement of progression * ECOG performance status of 0 to 1 Exclusion Criteria: * History of bleeding disorder or significant bleeding episode within 6 months prior to study treatment * Subjects receiving anticoagulants or medications that durably inhibit platelet function (7-day wash-out prior to study treatment) * History of or current leptomeningeal or brain metastasis or spinal cord compression.